133 related articles for article (PubMed ID: 16849642)
1. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.
Masih-Khan E; Trudel S; Heise C; Li Z; Paterson J; Nadeem V; Wei E; Roodman D; Claudio JO; Bergsagel PL; Stewart AK
Blood; 2006 Nov; 108(10):3465-71. PubMed ID: 16849642
[TBL] [Abstract][Full Text] [Related]
2. Statins inhibited the MIP-1α expression via inhibition of Ras/ERK and Ras/Akt pathways in myeloma cells.
Tsubaki M; Mashimo K; Takeda T; Kino T; Fujita A; Itoh T; Imano M; Sakaguchi K; Satou T; Nishida S
Biomed Pharmacother; 2016 Mar; 78():23-29. PubMed ID: 26898421
[TBL] [Abstract][Full Text] [Related]
3. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
Terpos E; Politou M; Viniou N; Rahemtulla A
Leuk Lymphoma; 2005 Dec; 46(12):1699-707. PubMed ID: 16263571
[TBL] [Abstract][Full Text] [Related]
4. Fcgamma receptor signaling in primary human microglia: differential roles of PI-3K and Ras/ERK MAPK pathways in phagocytosis and chemokine induction.
Song X; Tanaka S; Cox D; Lee SC
J Leukoc Biol; 2004 Jun; 75(6):1147-55. PubMed ID: 14982949
[TBL] [Abstract][Full Text] [Related]
5. MIP-1 alpha and myeloma bone disease.
Roodman GD; Choi SJ
Cancer Treat Res; 2004; 118():83-100. PubMed ID: 15043189
[TBL] [Abstract][Full Text] [Related]
6. AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma.
Choi SJ; Oba T; Callander NS; Jelinek DF; Roodman GD
Blood; 2003 May; 101(10):3778-83. PubMed ID: 12560229
[TBL] [Abstract][Full Text] [Related]
7. MIP-1alpha[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential release of TNF-alpha and LTB4.
Ramos CD; Canetti C; Souto JT; Silva JS; Hogaboam CM; Ferreira SH; Cunha FQ
J Leukoc Biol; 2005 Jul; 78(1):167-77. PubMed ID: 15831559
[TBL] [Abstract][Full Text] [Related]
8. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM.
Uneda S; Hata H; Matsuno F; Harada N; Mitsuya Y; Kawano F; Mitsuya H
Br J Haematol; 2003 Jan; 120(1):53-5. PubMed ID: 12492576
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
Zhu L; Somlo G; Zhou B; Shao J; Bedell V; Slovak ML; Liu X; Luo J; Yen Y
Mol Cancer Ther; 2005 May; 4(5):787-98. PubMed ID: 15897243
[TBL] [Abstract][Full Text] [Related]
10. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
[TBL] [Abstract][Full Text] [Related]
12. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
13. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Oyajobi BO; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
[TBL] [Abstract][Full Text] [Related]
14. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
[TBL] [Abstract][Full Text] [Related]
15. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
[TBL] [Abstract][Full Text] [Related]
16. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
[TBL] [Abstract][Full Text] [Related]
17. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.
Hashimoto T; Abe M; Oshima T; Shibata H; Ozaki S; Inoue D; Matsumoto T
Br J Haematol; 2004 Apr; 125(1):38-41. PubMed ID: 15015966
[TBL] [Abstract][Full Text] [Related]
18. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
[TBL] [Abstract][Full Text] [Related]
19. Chemokine and chemokine receptor expression by liver-derived dendritic cells: MIP-1alpha production is induced by bacterial lipopolysaccharide and interaction with allogeneic T cells.
Drakes ML; Zahorchak AF; Takayama T; Lu L; Thomson AW
Transpl Immunol; 2000 Mar; 8(1):17-29. PubMed ID: 10834607
[TBL] [Abstract][Full Text] [Related]
20. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
di Martino E; L'Hôte CG; Kennedy W; Tomlinson DC; Knowles MA
Oncogene; 2009 Dec; 28(48):4306-16. PubMed ID: 19749790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
